Freiberger, Sandra N.
Holzmann, David
Morand, Grégoire B.
Hüllner, Martin
Levesque, Mitchell P.
Dummer, Reinhard
Koelzer, Viktor H.
Rupp, Niels J.
Funding for this research was provided by:
Cancer League Zurich
University of Zurich
Article History
Received: 8 September 2022
Accepted: 2 December 2022
First Online: 17 December 2022
Declarations
:
: MH received grants from GE Healthcare, funding by the Alfred and Annemarie von Sick legacy for translational and clinical cardiac and oncological research and a grant by the Clinical Research Priority Program (CRRP) “Artificial Intelligence in oncological Imaging” of the University Zurich. MPL has received project-specific research funding from Roche, Novartis, Oncobit, and Molecular Partners outside the scope of this work. Prof. Dummer has intermittent, project focused consulting and/or advisory relationships with Novartis, Merck Sharp & Dhome (MSD), Bristol-Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, Alligator, T3 Pharma, MaxiVAX SA, Pfizer and touchIME outside the submitted work. SNF, DH, GBM, VHK, and NJR have no competing interests regarding this study.
: Ethical approval was given by the cantonal ethics commission (BASEC 2020–01663, approved: 30 July 2020) and all patients signed written informed consent (BASEC PB_2017-00494, amendment approved: 25 July 2017).